XML 12 R2.htm IDEA: XBRL DOCUMENT v3.8.0.1
Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)
Sep. 30, 2017
Jun. 30, 2017
Current assets:    
Cash and cash equivalents $ 2,464,000 $ 3,623,000
Accounts receivable, net of allowance for doubtful accounts of $139,000 ($102,000 at June 30, 2017) 3,404,000 3,701,000
Inventories, net of reserves of $1,257,000 ($1,230,000 at June 30, 2017) 4,157,000 3,617,000
Prepaid expenses and other current assets 282,000 237,000
Total current assets 10,307,000 11,178,000
Equipment, less accumulated depreciation 2,971,000 2,330,000
Preliminary goodwill 13,794,000 13,195,000
Intangible assets, net 21,809,000 20,165,000
Other assets 61,000 64,000
Total assets 48,942,000 46,932,000
Current liabilities:    
Accounts payable 2,038,000 1,601,000
Accrued payroll and related expenses 429,000 385,000
Deferred revenue 603,000 597,000
Related party payable 606,000 606,000
Other current liabilities 1,319,000 1,331,000
Total current liabilities 4,995,000 4,520,000
Long-term debt-related party 5,000,000 3,500,000
Noncurrent deferred tax liability 6,968,000 6,968,000
Derivative obligation 743,000 730,000
Other non-current liabilities 403,000 377,000
Total liabilities 18,109,000 16,095,000
Commitments and contingencies
Stockholders’ equity:    
Preferred stock, $0.001 par value; 2,000,000 shares authorized, none outstanding
Common stock, $0.001 par value; 350,000,000 shares authorized; 9,959,943 issued and outstanding (9,915,868 at June 30, 2017) 10,000 10,000
Paid in capital in excess of par 218,801,000 216,222,000
Accumulated deficit (187,707,000) (185,357,000)
Accumulated other comprehensive loss (34,000) (38,000)
Total Cesca Therapeutics Inc. stockholders’ equity 31,070,000 30,837,000
Noncontrolling interests (237,000)
Total equity 30,833,000 30,837,000
Total liabilities and stockholders’ equity $ 48,942,000 $ 46,932,000